Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer

Objectif

"Triple-Negative Breast Cancer (TNBC) remains one of the most challenging subtypes of oncology due to its high metastatic potential, lack of targeted receptors, and rapid development of drug resistance. The BioMIX project proposes a disruptive solution: a ""stealth"" biomimetic nanoplatform designed to bypass the immune system and deliver a potent combination of chemotherapy, gene therapy, and sonodynamic therapy (SDT) directly to the tumor site. The core of the BioMIX technology is a two-dimensional Ti3C2 MXene nanosheet, which serves as a structural scaffold and a high-efficiency sonosensitizer. This core is functionalized with a pH-responsive polydopamine shell to entrap Doxorubicin and a cationic layer to complex anti-MDR1 siRNA. To achieve superior targeting, the construct is ""camouflaged"" with a hybrid membrane fused from TNBC cells and macrophages, further enhanced with iRGD peptides for deep-tissue penetration. Upon reaching the tumor, low-intensity ultrasound is applied to trigger localized hyperthermia and reactive oxygen species (ROS) generation, causing controlled drug release and inducing targeted cancer cell apoptosis. As an MSCA Staff Exchange action, BioMIX is built on a highly interdisciplinary consortium of 13 international partners across the academic and industrial sectors. The project is structured to facilitate more than 200 person-months of knowledge transfer, conveying critical expertise in 2D materials science, microfluidic manufacturing, and preclinical oncology research. By integrating ""Tumor-on-a-Chip"" validation and in vivo efficacy studies, BioMIX aims to establish a clinically translatable framework for targeted nanomedicine while reducing the systemic side effects (such as cardiotoxicity) of conventional chemotherapy. The project’s outcomes will strengthen European leadership in nanobiotechnology and provide a scalable framework for the next generation of biomimetic therapeutic vehicles aligned with Europe’s Beating Cancer Plan."

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-MSCA-2026-SE-01

Voir tous les projets financés au titre de cet appel

Coordinateur

LATVIJAS UNIVERSITATE
Contribution nette de l'UE
€ 155 100,00
Coût total
Aucune donnée

Participants (10)

Partenaires (2)